Fact CheckerSign in

NCT07504263Not yet recruitingPhase 1/2

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies

Source: ClinicalTrials.gov · Last updated 31 Mar 2026

Brief summary (registry, in English)

Phase 1/2a Study of RP-001 in participants with Advanced Malignancies

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
66 (estimated)
First submitted
21 Mar 2026
Start date
23 Apr 2026
Primary completion date
1 Dec 2027
Lead sponsor
Recurv Pharma Inc
NCT number
NCT07504263
EU CT number
2025-520668-16-00

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 66
  • From 23 Apr 2026 to the primary completion date, 1 Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • 1\. Active infection requiring systemic anti-infective therapy within 28 days prior to first dose of RP-001.
    • 2\. Cardiovascular disease, including:
    • Unstable angina; b. symptomatic peripheral arterial vascular disease; c. Myocardial infarction within 6 months prior to RP-001 administration; d. New York Heart Association Class III or IV heart failure; e. Uncontrolled arrythmia; f. ECG abnormality that, in the opinion of the Investigator, increases the risks associated with participating in the trial.
    • 3\. Concurrent systemic anti-cancer therapy other than luteinizing hormone-releasing hormone (LH-RH) agonists.
    • 4\. Pregnancy, or breastfeeding. 5. Untreated central nervous system metastasis, or carcinomatous meningitis. 6. Any concurrent severe and/or uncontrolled medical or surgical condition which, in the opinion of the Investigator, may compromise the participant's involvement in the trial due to safety, compliance concerns or ability to evaluate response.

Who the study is looking for

  • Male or female participants aged 18 years or older with advanced or metastatic cancer, which must be measurable per RECIST v1.1 and satisfy the following criteria:
    • Phase 1: Participants with solid tumors who are candidates for treatment with a taxane
    • Phase 2a: Participants with relapsed or refractory PDAC, or CRC.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.